The global endoglin precursor market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of cardiovascular diseases and cancer, which are major drivers for the endoglin precursor market. The increasing number of patients with cardiovascular diseases and cancer will lead to an increase in demand for endoglin precursors, thereby driving the growth of this market.
The global endoglin precursor market has been segmented on the basis of type into above 90%, above 95%, and above 99%. Above 90% segment accounted for a share of over 50% in 2018 and is expected to maintain its dominance throughout the forecast period owing to its high demand in biopharmaceutical companies as well as hospitals. Above 95% segment accounted for a share close to 30% in 2018 and is expected to grow at a CAGR close to 6%. Above 99% segment accounted for less than 10% share in 2018 but it is anticipated that it will grow at a CAGR close to 7%.
On the basis on application, biopharmaceutical companies accounted for over 50% share in 2018 due their high demand from pharmaceutical companies across different regions such as North America, Europe, Asia Pacific (APAC), Latin America (LA), Middle East & Africa (MEA). Hospitals account for around 30-35%, while bioscience research institutions account for less than 10%. On regional front North America dominated with more than 40-45%; followed by Europe with around 25%; APAC with 15%; LA with 10%; MEA with 5-10%.
2) Increasing prevalence of cardiovascular diseases and diabetes are major factors driving the growth of global endoglin market.
Some Of The Growth Factors Of This Market:
- Increasing awareness about the benefits of endoglin in cardiovascular diseases and diabetes is also expected to fuel its growth over the forecast period (2018-2025).
Industry Growth Insights published a new data on “ENG(Endoglin precursor) Market”. The research report is titled “ENG(Endoglin precursor) Market research by Types (Above 90%, Above 95%, Above 99%, Others), By Applications (Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others), By Players/Companies Aviva Systems Biology Corporation(USA), Atlas Antibodies(Sweden), Abbexa Ltd(UK), Abiocode(US), Boster Biological Technology(USA), Biobyt(UK), Bio-Rad(US), Bioss Antibodies(US), Biosensis(US), BioLegend(US), BioVision(US), BethylLaboratories(US), Epigentek(US), EnzoLifeSciences(Switzerland), Genetex(US), Lifespan Biosciences(US), Novus Biologicals(US), Proteintech(US), ProSci(US), ProteoGenix(France), R&D Systems(US), Rockland(US), St John's Laboratory Ltd(UK), Stemcell(Canada), Thermo Fisher Scientific(US), USBiological(US)”.
Scope Of The Report
Report Attributes
Report Details
Report Title
ENG(Endoglin precursor) Market Research Report
By Type
Above 90%, Above 95%, Above 99%, Others
By Application
Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others
By Companies
Aviva Systems Biology Corporation(USA), Atlas Antibodies(Sweden), Abbexa Ltd(UK), Abiocode(US), Boster Biological Technology(USA), Biobyt(UK), Bio-Rad(US), Bioss Antibodies(US), Biosensis(US), BioLegend(US), BioVision(US), BethylLaboratories(US), Epigentek(US), EnzoLifeSciences(Switzerland), Genetex(US), Lifespan Biosciences(US), Novus Biologicals(US), Proteintech(US), ProSci(US), ProteoGenix(France), R&D Systems(US), Rockland(US), St John's Laboratory Ltd(UK), Stemcell(Canada), Thermo Fisher Scientific(US), USBiological(US)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global ENG(Endoglin precursor) Market Report Segments:
The global ENG(Endoglin precursor) market is segmented on the basis of:
Types
Above 90%, Above 95%, Above 99%, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aviva Systems Biology Corporation(USA)
- Atlas Antibodies(Sweden)
- Abbexa Ltd(UK)
- Abiocode(US)
- Boster Biological Technology(USA)
- Biobyt(UK)
- Bio-Rad(US)
- Bioss Antibodies(US)
- Biosensis(US)
- BioLegend(US)
- BioVision(US)
- BethylLaboratories(US)
- Epigentek(US)
- EnzoLifeSciences(Switzerland)
- Genetex(US)
- Lifespan Biosciences(US)
- Novus Biologicals(US)
- Proteintech(US)
- ProSci(US)
- ProteoGenix(France)
- R&D Systems(US)
- Rockland(US)
- St John's Laboratory Ltd(UK)
- Stemcell(Canada)
- Thermo Fisher Scientific(US)
- USBiological(US)
 Market Overview.svg)
Highlights of The ENG(Endoglin precursor) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Above 90%
- Above 95%
- Above 99%
- Others
- By Application:
- Biopharmaceutical Companies
- Hospitals
- Bioscience Research Institutions
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the ENG(Endoglin precursor) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
ENG is a protein that is found in the blood and can be used to diagnose or monitor diseases. ENG can also be used to help treat diseases.
Some of the key players operating in the eng(endoglin precursor) market are Aviva Systems Biology Corporation(USA), Atlas Antibodies(Sweden), Abbexa Ltd(UK), Abiocode(US), Boster Biological Technology(USA), Biobyt(UK), Bio-Rad(US), Bioss Antibodies(US), Biosensis(US), BioLegend(US), BioVision(US), BethylLaboratories(US), Epigentek(US), EnzoLifeSciences(Switzerland), Genetex(US), Lifespan Biosciences(US), Novus Biologicals(US), Proteintech(US), ProSci(US), ProteoGenix(France), R&D Systems(US), Rockland(US), St John's Laboratory Ltd(UK), Stemcell(Canada), Thermo Fisher Scientific(US), USBiological(US).
The eng(endoglin precursor) market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. ENG(Endoglin precursor) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. ENG(Endoglin precursor) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. ENG(Endoglin precursor) Market - Supply Chain
4.5. Global ENG(Endoglin precursor) Market Forecast
4.5.1. ENG(Endoglin precursor) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. ENG(Endoglin precursor) Market Size (000 Units) and Y-o-Y Growth
4.5.3. ENG(Endoglin precursor) Market Absolute $ Opportunity
5. Global ENG(Endoglin precursor) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. ENG(Endoglin precursor) Market Size and Volume Forecast by Type
5.3.1. Above 90%
5.3.2. Above 95%
5.3.3. Above 99%
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global ENG(Endoglin precursor) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. ENG(Endoglin precursor) Market Size and Volume Forecast by Application
6.3.1. Biopharmaceutical Companies
6.3.2. Hospitals
6.3.3. Bioscience Research Institutions
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global ENG(Endoglin precursor) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. ENG(Endoglin precursor) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global ENG(Endoglin precursor) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. ENG(Endoglin precursor) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global ENG(Endoglin precursor) Demand Share Forecast, 2019-2026
9. North America ENG(Endoglin precursor) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America ENG(Endoglin precursor) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America ENG(Endoglin precursor) Market Size and Volume Forecast by Application
9.4.1. Biopharmaceutical Companies
9.4.2. Hospitals
9.4.3. Bioscience Research Institutions
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America ENG(Endoglin precursor) Market Size and Volume Forecast by Type
9.7.1. Above 90%
9.7.2. Above 95%
9.7.3. Above 99%
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America ENG(Endoglin precursor) Demand Share Forecast, 2019-2026
10. Latin America ENG(Endoglin precursor) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America ENG(Endoglin precursor) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America ENG(Endoglin precursor) Market Size and Volume Forecast by Application
10.4.1. Biopharmaceutical Companies
10.4.2. Hospitals
10.4.3. Bioscience Research Institutions
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America ENG(Endoglin precursor) Market Size and Volume Forecast by Type
10.7.1. Above 90%
10.7.2. Above 95%
10.7.3. Above 99%
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America ENG(Endoglin precursor) Demand Share Forecast, 2019-2026
11. Europe ENG(Endoglin precursor) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe ENG(Endoglin precursor) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe ENG(Endoglin precursor) Market Size and Volume Forecast by Application
11.4.1. Biopharmaceutical Companies
11.4.2. Hospitals
11.4.3. Bioscience Research Institutions
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe ENG(Endoglin precursor) Market Size and Volume Forecast by Type
11.7.1. Above 90%
11.7.2. Above 95%
11.7.3. Above 99%
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y rowth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe ENG(Endoglin precursor) Demand Share, 2019-2026
12. Asia Pacific ENG(Endoglin precursor) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific ENG(Endoglin precursor) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific ENG(Endoglin precursor) Market Size and Volume Forecast by Application
12.4.1. Biopharmaceutical Companies
12.4.2. Hospitals
12.4.3. Bioscience Research Institutions
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific ENG(Endoglin precursor) Market Size and Volume Forecast by Type
12.7.1. Above 90%
12.7.2. Above 95%
12.7.3. Above 99%
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific ENG(Endoglin precursor) Demand Share, 2019-2026
13. Middle East & Africa ENG(Endoglin precursor) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa ENG(Endoglin precursor) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa ENG(Endoglin precursor) Market Size and Volume Forecast by Application
13.4.1. Biopharmaceutical Companies
13.4.2. Hospitals
13.4.3. Bioscience Research Institutions
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa ENG(Endoglin precursor) Market Size and Volume Forecast by Type
13.7.1. Above 90%
13.7.2. Above 95%
13.7.3. Above 99%
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa ENG(Endoglin precursor) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global ENG(Endoglin precursor) Market: Market Share Analysis
14.2. ENG(Endoglin precursor) Distributors and Customers
14.3. ENG(Endoglin precursor) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Aviva Systems Biology Corporation(USA)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Atlas Antibodies(Sweden)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Abbexa Ltd(UK)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Abiocode(US)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Boster Biological Technology(USA)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biobyt(UK)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bio-Rad(US)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bioss Antibodies(US)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Biosensis(US)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. BioLegend(US)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. BioVision(US)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. BethylLaboratories(US)
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Epigentek(US)
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. EnzoLifeSciences(Switzerland)
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Genetex(US)
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Lifespan Biosciences(US)
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Novus Biologicals(US)
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Proteintech(US)
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. ProSci(US)
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. ProteoGenix(France)
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
